Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Coordination and Support Action · Finished

GATBIO NEXT GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing

Coordinator
Gat Biosciences SL, Spain
Runs
1 June 2023 to 31 May 2024
Status
Finished
EU funding
€75k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101114204

What the project is doing

In the project's own words, from its summary on CORDIS.

GAT Biosciences (GATBIO) is a women-led Biotech SME targeting the exploitation of its proprietary GRTTM technology as a novel solution for the development and production of complex biologic drugs for biopharma and veterinary markets. Specifically, we are developing a game-changer next generation of accessible and non-invasive (oral, topic, inhaled) biopharmaceuticals through proprietary and sustainable microalgae biofactories.

Our first candidate for the biopharmaceutical Market, GB-AF-004, will enter pre-clinical demonstration in 2023. GB-AF-004 is an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases and Disorders (IBDs). The term IBDs includes a range of chronic and painful autoimmune diseases affecting localy the intestine, affecting patients from their youth and throughout life and of unknown causess. More than 6 million people are affected by IBDs globally and their global treatment market is estimated by 2029 at 37 billion euros per year.

GB-AF-004 has the potential to be a game-changer in the treatment of this high prevalence and chronic inflammatory intestinal diseases. GATBIO has been recently granted a Seal of Excellence from the EIC accelerator Program supporting disruptive European SMEs for their acceleration to the market. The related funding will allow us to enter the preclinical development of GB-AF-004 early in 2023. In this frame, additional support related not to scientific development per se but to reinforcing our strategic business management and vision could be key to success in our next steps and culminate GB-AF-004 out-licensing.

Specifically, to access Expert mentoring and Biomed advice related to i) clinical positioning in the IBD market and ii) out-licensing strategy, would be key to success in the arrival of our 1st candidate to the regulated market and would translate into GATBIO’s consolidation and exponential growth based on innovation out-licensing.

Who is involved

OrganisationCityCountryRole
Gat Biosciences SLBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI